The Technical Analyst
Select Language :

NextCure Inc [NXTC]
- Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Exchange: NasdaqGS ->Biotechnology

Last updated: 27 Oct 2021 @ 03:11 am

NextCure Inc is listed at the NASDAQ Exchange

-3.13% $7.73


FUNDAMENTALS
MarketCap: 213.44 mill
EPS: -2.41
P/E: 0.000
Earnings Date: Aug 05, 2021
SharesOutstanding: 27.61 mill
Avg Daily Volume: 0.240 mill
RATING 2021-10-25
B+
Neutral
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Buy
QUARTER GROWTHS
1/202/203/204/201/212/21
Revenuen/an/an/a
Gr.Profitn/an/an/an/an/a
Ebit
Asset
Debt

Insider Trading

Date Person Action Amount type
2021-10-01 Feigal Ellen Buy 10 384 Stock Option (Right to Buy)
2021-10-01 Feigal Ellen Buy 28 500 Stock Option (Right to Buy)
2021-10-01 Borgman Anne Elizabeth Buy 10 384 Stock Option (Right to Buy)
2021-10-01 Borgman Anne Elizabeth Buy 28 500 Stock Option (Right to Buy)
2021-07-15 Kundu Sourav Buy 150 000 Employee Stock Option (Right to Buy)
INSIDER POWER
0.657
Last 86 transactions
Buy: 16 250 780 | Sell: 24 735 099

Forecast: 16:00 - $7.73

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $7.73
Forecast 2: 16:00 - $7.73
Forecast 3: 16:00 - $7.73
SCORE
-7.50
Sell
Score Algorithm Version: 0.9L
Last version updated: Wed 21th July 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $7.73 (-3.13% )
Volume 0.390 mill
Avg. Vol. 0.240 mill
% of Avg. Vol 162.84 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for NextCure Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for NextCure Inc

RSI

Intraday RSI14 chart for NextCure Inc
The Live Chart for NextCure Inc
Profile picture for
            NextCure Inc

NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.

Last 10 Buy Signals
Date Signal @
DOGEUSDOct 26 - 23:08$0.258
XRPUSDOct 26 - 23:051.113
DOGEUSDOct 26 - 22:50$0.258
BTCUSDOct 26 - 22:3060 576
XRPUSDOct 26 - 21:571.116
BTCUSDOct 26 - 21:5460 607
DOGEUSDOct 26 - 21:12$0.258
BTCUSDOct 26 - 21:0760 705
XRPUSDOct 26 - 20:481.112
DOGEUSDOct 26 - 20:45$0.258

Stock Peers

Company Price Change
NXTC7.73-3.13%
AKU1.750-2.78%
AVEO6.721.51%
CASI1.060-0.93%
EDAP6.140.82%
HROW9.700.10%
NEPT0.543-7.97%
SLGL8.99-0.86%
TLSA1.620-1.82%
TYME0.964-1.25%
XERS1.870-2.60%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.